Epidemiological observations and laboratory research have suggested that nonsteroidal
anti-inflammatory drugs (NSAIDs) reduce the risk of colon cancer and that the inhibition of …

Epidemiological and laboratory studies suggest that nonsteroidal anti-inflammatory drugs
reduce the risk of colon cancer and that the inhibition of colon carcinogenesis is mediated …

Population-based studies have established that long-term intake of non-steroidal anti-
inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of …

The regular use of various nonsteroidal anti‐inflammatory drugs (NSAIDs) was shown to
decrease the incidence of colorectal cancer. This effect is thought to be caused …

During recent years, multidisciplinary studies in epidemiology and molecular biology, as
well as preclinical studies, have contributed much to our understanding of the etiology of …

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-
inflammatory drug so far which has been approved by the FDA for adjuvant treatment of …

Nonsteroidal anti-inflammatory drugs have potential for use in the prevention and/or
treatment of colorectal cancer. We have studied the cytotoxic effect of a specific COX-2 …

Epidemiological and laboratory studies indicate an inverse relationship between the risk of
colon cancer development and intake of nonsteroidal antiinflammatory agents, including …

BACKGROUND & AIMS: Multiple studies show that continuous use of nonsteroidal anti-
inflammatory drugs (NSAIDs) lowers the risk of colon cancer in humans and carcinogen …

Abstract Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the
anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory …